Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
Ascendiant Capital Markets raised its price target on IGC Pharma to $5.50, citing potential clinical catalysts in 2026. The firm highlighted the company's lead program IGC-AD1, which is currently in the Phase 2 CALMA trial for agitation associated with Alzheimer's disease.
Key figures
- Price target
- 5.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.